- Blended Gross Margins on the suite of products offered by Sonomax are currently 48%, more or less, with the exception of EarFit® fit-validation which is sold in the context of a software licensing model, the cost substantially embedded in previous investment.

- Based upon, and subject to, achievement of projected sales growth, the company's overheads in 2008 have been modeled to increase to about $650K/month.

- The company currently has 145 million Class A common shares issued and outstanding, and 65 million unexercised options and warrants; in sum, 210 million common shares on a fully diluted basis.

- Financial projections indicate an EBTDA of 2 cents per issued and outstanding share, 1.5 cents on a fully diluted basis, EBTDA considered to be the most relevant metric by reason of the company's $22 million+ of tax losses carried forward.

- 49 million options and warrants are currently at or in the money; if exercised this translates to $14 million, or 7 cents per then outstanding share, in cash to the company.

- If and when the remaining 16 million options and warrants are exercised, the cash to the company will increase to $22 million, or 10.5 cents per share.

About Sonomax:

Sonomax Hearing Healthcare Inc. is a leader in the development and manufacturing of intra-ear technology. The company's patented custom-fit, instant-fit expansion earpieces deliver a perfect acoustic seal every time and can be certified by SonoPass®, the company's proprietary, computer generated proof-of-performance software. Building on its technology leadership in hearing protection, Sonomax has expanded the applications for its technologies into high growth consumer markets such as MP3 audio, multi-media and gaming earphones, as well as Bluetooth® headsets for telephony, through its subsidiary VitaSound Audio Inc.

Forward-Looking Statements:

Certain statements included herein, including those that express management's expectations or estimates of our future performance, constitute "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies. We caution that such forward-looking statements involve known and unknown risks, uncertainties and other risks that may cause our actual financial results, performance, or achievements to be materially different from our estimated future results, performance or achievements expressed or implied by those forward-looking statements. Numerous factors could cause actual results to differ materially from those in the forward-looking statements, including without limitation, our ability to achieve increased market acceptance for our product offerings and penetrate new markets; the existence of undetected errors or similar problems in our products; our ability to manage our growth; our ability to compete successfully; potential liabilities; maintaining our intellectual property rights and litigation involving intellectual property rights; our dependence on the expertise of our key personnel; and our access to sufficient capital to fund our future requirements. This list is not exhaustive of the factors that may affect any of our forward-looking statements. Investors are cautioned not to put undue reliance on forward-looking statements. All subsequent written and oral forward-looking statements attributable to Sonomax or persons acting on our behalf are expressly qualified in their entirety by this notice. Other than as may be required by applicable laws, we disclaim any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of Sonomax Hearing Healthcare Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.